PureTech Health (GB:PRTC) has released an update.
PureTech Health plc has reported that as of April 30, 2024, its share capital consists of 289,468,159 Ordinary Shares, with 19,055,414 shares held in treasury, resulting in a total of 270,412,745 voting rights. The company, a clinical-stage biotherapeutics entity, is focused on developing a diverse pipeline of 29 therapeutics, including two with U.S. FDA clearance and European marketing authorization, and one filed for FDA approval. Shareholders are advised that this information is pertinent for calculating notifications related to changes in their interest under the FCA’s Disclosure Guidance and Transparency Rules.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
